Genmab A/S’s (GMAB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Wednesday morning, Marketbeat.com reports. The brokerage currently has a $39.00 target price on the stock.

A number of other equities research analysts also recently weighed in on GMAB. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Truist Financial reissued a “buy” rating and issued a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.25.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $32.93 on Wednesday. The stock has a market capitalization of $21.15 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 19.37 and a beta of 0.90. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43. The stock has a fifty day moving average of $32.36 and a 200-day moving average of $28.94.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.17. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. Equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. M&T Bank Corp increased its holdings in shares of Genmab A/S by 88.8% in the fourth quarter. M&T Bank Corp now owns 15,034 shares of the company’s stock worth $463,000 after acquiring an additional 7,073 shares in the last quarter. Eagle Global Advisors LLC lifted its holdings in shares of Genmab A/S by 2.0% during the 4th quarter. Eagle Global Advisors LLC now owns 249,310 shares of the company’s stock valued at $7,679,000 after purchasing an additional 4,840 shares in the last quarter. Evergreen Capital Management LLC grew its position in shares of Genmab A/S by 14.0% in the 4th quarter. Evergreen Capital Management LLC now owns 22,350 shares of the company’s stock valued at $688,000 after purchasing an additional 2,752 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Genmab A/S by 75.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,840 shares of the company’s stock worth $87,000 after purchasing an additional 1,219 shares in the last quarter. Finally, CWM LLC raised its holdings in Genmab A/S by 18.8% during the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after buying an additional 433 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.